Literature DB >> 26293899

The clinical utility of RFA in esophageal and cardia cancer patients with severe malignant obstruction.

Hongxin Niu1, Xikun Zhang1, Bin Wang1, Zhao Zhou1, Jian Wang1, Xiangshan Yang2, Tong Du3.   

Abstract

Malignant obstruction of esophageal and cardia cancer greatly affects the prognosis and life quality of patients. However, no better regimens have been reported up to now. In recent years, radiofrequency ablation (RFA) has been prospectively proven in the management of some tumors. So, we investigated the impact of RFA on the malignant obstruction of esophageal and cardia cancer. In this study, we evaluated the operation duration, ablation duration, immediate compilations, etc., and followed up for 12 months. Our findings showed that there existed no technical problems in all 22 patients with a mean operation duration of 58 min and mean ablation duration of 23 min. No complication was observed in addition to postoperative low pressure in one patient and retrostenal pain in another patient. Importantly, all 22 patients obtained complete remission with normal diet and felt no sense of obstruction. Mean hospitalization time was 3 days and then the 12-month follow-up continued. To our relief, re-obstruction was not observed in all patients for 2 months. In conclusion, the entire effect of RFA was satisfactory, and patients can obtain a better life quality, less pains, and complications. So RFA should be advocated and greatly investigated by more institutes and hospitals.

Entities:  

Keywords:  Esophageal and cardia cancer; Malignant obstruction; RFA

Mesh:

Substances:

Year:  2015        PMID: 26293899     DOI: 10.1007/s13277-015-3925-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  9 in total

1.  Palliative esophageal stent or surgery in advanced esophageal malignancy.

Authors:  A Manomaipiboon; S Wattanasirichaigoon; S Srisaovajate; W Thanapongsathorn; W Nggitphaiboon; Y Sangpayup
Journal:  J Med Assoc Thai       Date:  2001-10

2.  Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles.

Authors:  Evan S Glazer; Katheryn L Massey; Cihui Zhu; Steven A Curley
Journal:  Surgery       Date:  2010-06-11       Impact factor: 3.982

3.  Impact of a self-expanding, plastic esophageal stent on various esophageal stenoses, fistulas, and leakages: a single-center experience in 39 patients.

Authors:  Klaus Radecke; Guido Gerken; Ulrich Treichel
Journal:  Gastrointest Endosc       Date:  2005-06       Impact factor: 9.427

Review 4.  Radiofrequency ablation for breast cancer.

Authors:  Ann M Leylek; Gary J Whitman; Vanessa S Vilar; Nestor Kisilevzky; Salomao Faintuch
Journal:  Tech Vasc Interv Radiol       Date:  2013-12

5.  Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract.

Authors:  Lene Larssen; Asle W Medhus; Hartwig Körner; Tom Glomsaker; Taran Søberg; Dagfinn Gleditsch; Øistein Hovde; Jan K Tholfsen; Knut Skreden; Arild Nesbakken; Truls Hauge
Journal:  Scand J Gastroenterol       Date:  2012-10-10       Impact factor: 2.423

6.  Pilot study for a new bipolar radiofrequency ablation/aspirator device in the management of primary and secondary liver cancers.

Authors:  Dimitris Zacharoulis; Shirin E Khorsandi; Petr Vavra; Jan Dostalik; Giuseppe Navarra; Joanna P Nicholls; Long R Jiao; Nagy A Habib
Journal:  Liver Int       Date:  2009-07       Impact factor: 5.828

7.  Radiofrequency ablation of liver tumors using a novel bipolar device.

Authors:  Robert M Eisele; Peter Neuhaus; Guido Schumacher
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2008-12       Impact factor: 1.878

8.  Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria.

Authors:  Shinichi Ueno; Masahiko Sakoda; Fumitake Kubo; Kiyokazu Hiwatashi; Taro Tateno; Yoshiro Baba; Susumu Hasegawa; Hirohito Tsubouchi
Journal:  J Hepatobiliary Pancreat Surg       Date:  2009-03-20

9.  New and emerging combination therapies for esophageal cancer.

Authors:  Marcus W Wiedmann; Joachim Mössner
Journal:  Cancer Manag Res       Date:  2013-06-27       Impact factor: 3.989

  9 in total
  1 in total

1.  The involvement of anterior gradient 2 in the stromal cell-derived factor 1-induced epithelial-mesenchymal transition of glioblastoma.

Authors:  Chunhua Xu; Yue Liu; Limin Xiao; Changgui Guo; Shengze Deng; Suyue Zheng; Erming Zeng
Journal:  Tumour Biol       Date:  2015-11-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.